Clinical applications of recombinant CSF1-Fc produced in the eggs of transgenic hens in veterinary and human medicine

Lead Research Organisation: University of Edinburgh
Department Name: The Roslin Institute


Biologics are pharmaceutical proteins very effective at treating a number of previously intractable medical conditions. They are an increasing proportion of the human drugs market, but widespread use in veterinary settings has been prevented by high production cost. Replacing the expensive mammalian cell culture systems with transgenic chickens has significant potential to reduce this cost. With our system, hens can produce protein of consistent quantity and activity over their entire laying lives, and purification is performed using standard techniques. Here we propose to take forward our recent success producing active pig CSF1-Fc in transgenic hens' eggs by purifying large quantities and testing in potential applications. We will scale up purification, perform full quality control, test in pig models of human disease, and provide material to other experts for evaluation. We will also produce a new transgenic line expressing dog CSF1-Fc for future studies in veterinary medicine.


10 25 50
Description We have shown that recombinant protein synthesised by GM hens as a component of egg white can be purified using technology that is scalable for commercial production. Purified protein is of high quality and purity and of predicted biological activity.
Exploitation Route The technologies developed may be used as a platform technology for producing biologics for the reagents and animal health markets. We are actively seeking additional partners and funding to advance this.
Sectors Agriculture, Food and Drink,Pharmaceuticals and Medical Biotechnology

Description Purification technologies 
Organisation Centre for Process Innovation (CPI)
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Private 
PI Contribution We developed lab scale purification of recombinant proteins from the eggs of transgenic hens.
Collaborator Contribution Working with the CPI we have developed a scalable purification process, yielding high quality, pure and biologically active recombinant protein.
Impact Outcomes will be described in publications in 2017.
Start Year 2015